A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Small Cell Lung Cancer(ALTER1202)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2018
At a glance
- Drugs Anlotinib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms ALTER1202
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 26 Jul 2018 Planned End Date changed from 1 Apr 2018 to 30 Dec 2018.
- 26 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Mar 2017 Status changed from not yet recruiting to recruiting.